secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spyre Therapeutics, Inc. (SYRE)
CIK:        0001636282
Form:       8-K
Filed at:   2023-11-24T23:59:59+00:00
Accession:  0001193125-23-282424
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.03, 5.07, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aeglea shareholders approve increase in authorized shares to 400M and preferred conversion
--------------------------------------------------------------------------------

- Authorized common shares increased from 20M to 400M via Certificate of Amendment.
- Stockholders approved issuance of up to 43.45M shares upon conversion of Series A Preferred Stock.
- Amendment and restatement of 2016 Equity Incentive Plan approved.
- Pro forma shares outstanding ~47.8M after full Series A conversion and pre-funded warrant exercise.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636282/000119312523282424/0001193125-23-282424-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636282/000119312523282424/d23731d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-282424

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer